{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:27:52Z","timestamp":1793834872783,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osimertinib, also known as AZD9291, is a highly potent and selective EGFR mutants (including exon 19 deletion, L858R\/T790M) inhibitor that significantly inhibits EGFR phosphorylation signaling. However, acquired resistance to osimertinib is inevitable in the treatment of non-small cell lung cancer (NSCLC). Microtubules, key cytoskeletal components involved in intracellular cargo transport, mediate EGFR-endosomal recycling, yet their specific role in osimertinib resistance remains to be elucidated. In this study, we found that centrosomal microtubule formation was increased in osimertinib-resistant NSCLC cells, and calmodulin-regulated spectrin-associated protein 3 (CAMSAP3) was identified as the key molecule responsible for the change of microtubule morphology. Genetic modulation via CAMSAP3 silencing in both osimertinib-sensitive cells (in vitro) and xenograft models (in vivo) enhanced microtubule clustering and resistance to osimertinib, whereas CAMSAP3 overexpression in resistant cells partially restored microtubule organization and drug sensitivity. Furthermore, we demonstrated that full-length CAMSAP3 is essential for proper localization of the microtubule-dependent endosomal-lysosomal system. CAMSAP3 depletion caused EGFR translocation to the perinuclear microtubule organizing center (MTOC), thereby blocking plasma membrane recycling and promoting lysosomal degradation. These findings establish CAMSAP3 as a key regulator of EGFR signaling and osimertinib response in NSCLC, suggesting its therapeutic potential for overcoming drug resistance in lung cancer.<\/jats:p>","DOI":"10.1038\/s41419-025-08299-0","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T10:05:44Z","timestamp":1765447544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cytoskeletal remodeling via CAMSAP3 downregulation drives resistance to osimertinib in NSCLC cells"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4241-6277","authenticated-orcid":false,"given":"Fei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanwu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangang","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0531-4263","authenticated-orcid":false,"given":"Huadong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"8299_CR1","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/S0960-894X(01)00344-4","volume":"11","author":"AJ Barker","year":"2001","unstructured":"Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett. 2001;11:1911\u20134.","journal-title":"Bioorg Med Chem Lett"},{"key":"8299_CR2","first-page":"4838","volume":"57","author":"JD Moyer","year":"1997","unstructured":"Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997;57:4838\u201348.","journal-title":"Cancer Res"},{"key":"8299_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10637-016-0350-y","volume":"34","author":"BM Ku","year":"2016","unstructured":"Ku BM, Bae YH, Koh J, Sun JM, Lee SH, Ahn JS, et al. AZD9291 overcomes T790M-mediated resistance through degradation of EGFR(L858R\/T790M) in non-small cell lung cancer cells. Invest N. Drugs. 2016;34:407\u201315.","journal-title":"Invest N. Drugs"},{"key":"8299_CR4","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1097\/JTO.0b013e31829f691f","volume":"8","author":"X Ye","year":"2013","unstructured":"Ye X, Zhu ZZ, Zhong L, Lu Y, Sun Y, Yin X, et al. High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact? J Thorac Oncol. 2013;8:1118\u201320.","journal-title":"J Thorac Oncol"},{"key":"8299_CR5","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1073\/pnas.0709662105","volume":"105","author":"CH Yun","year":"2008","unstructured":"Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA. 2008;105:2070\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8299_CR6","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1021\/acs.jmedchem.1c00876","volume":"65","author":"M Shaikh","year":"2022","unstructured":"Shaikh M, Shinde Y, Pawara R, Noolvi M, Surana S, Ahmad I, et al. Emerging approaches to overcome acquired drug resistance obstacles to osimertinib in non-small-cell lung cancer. J Med Chem. 2022;65:1008\u201346.","journal-title":"J Med Chem"},{"key":"8299_CR7","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.2217\/fon.15.250","volume":"11","author":"J Remon","year":"2015","unstructured":"Remon J, Planchard D. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients. Future Oncol. 2015;11:3069\u201381.","journal-title":"Future Oncol"},{"key":"8299_CR8","doi-asserted-by":"publisher","first-page":"102557","DOI":"10.1016\/j.ctrv.2023.102557","volume":"116","author":"Z Zalaquett","year":"2023","unstructured":"Zalaquett Z, Catherine Rita Hachem M, Kassis Y, Hachem S, Eid R, Raphael Kourie H, et al. Acquired resistance mechanisms to osimertinib: The constant battle. Cancer Treat Rev. 2023;116:102557.","journal-title":"Cancer Treat Rev"},{"key":"8299_CR9","doi-asserted-by":"publisher","first-page":"602924","DOI":"10.3389\/fonc.2021.602924","volume":"11","author":"MGO Fernandes","year":"2021","unstructured":"Fernandes MGO, Sousa C, Jacob M, Almeida L, Santos V, Ara\u00fajo D, et al. Resistance profile of osimertinib in pre-treated patients with EGFR T790M-mutated non-small cell lung cancer. Front Oncol. 2021;11:602924.","journal-title":"Front Oncol"},{"key":"8299_CR10","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1021\/acschembio.2c00479","volume":"17","author":"Z Wang","year":"2022","unstructured":"Wang Z, Lei P, Li Z, Han X, Yang F, Su T, et al. Proteomic and Phosphoproteomic analyses reveal the oncogenic role of PTK7-NDRG1 axis in non-small-cell lung cancer cell resistance to AZD9291. ACS Chem Biol. 2022;17:2849\u201362.","journal-title":"ACS Chem Biol"},{"issue":"5","key":"8299_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00418-008-0401-3","volume":"129","author":"K Roepstorff","year":"2008","unstructured":"Roepstorff K, Gr\u00f8vdal L, Grandal M, Lerdrup M, van Deurs B. Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol. 2008;129(5):563\u201378.","journal-title":"Histochem Cell Biol"},{"issue":"1","key":"8299_CR12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41392-020-00251-2","volume":"5","author":"N Yao","year":"2020","unstructured":"Yao N, Wang CR, Liu MQ, Li YJ, Chen WM, Li ZQ, et al. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth. Signal Transduct Target Ther. 2020;5(1):214.","journal-title":"Signal Transduct Target Ther"},{"key":"8299_CR13","doi-asserted-by":"publisher","first-page":"6968","DOI":"10.1038\/sj.onc.1210503","volume":"26","author":"K Shtiegman","year":"2007","unstructured":"Shtiegman K, Kochupurakkal BS, Zwang Y, Pines G, Starr A, Vexler A, et al. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene. 2007;26:6968\u201378.","journal-title":"Oncogene."},{"key":"8299_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.devcel.2014.01.001","volume":"28","author":"K Jiang","year":"2014","unstructured":"Jiang K, Hua S, Mohan R, Grigoriev I, Yau KW, Liu Q, et al. Microtubule minus-end stabilization by polymerization-driven CAMSAP deposition. Dev Cell. 2014;28:295\u2013309.","journal-title":"Dev Cell"},{"key":"8299_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1042\/EBC20190016","volume":"63","author":"C Garcin","year":"2019","unstructured":"Garcin C, Straube A. Microtubules in cell migration. Essays Biochem. 2019;63:509\u201320.","journal-title":"Essays Biochem"},{"issue":"6","key":"8299_CR16","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.7150\/thno.38729","volume":"10","author":"TM Chin","year":"2020","unstructured":"Chin TM, Boopathy GTK, Man EPS, Clohessy JG, Csizmadia E, Quinlan MP, et al. Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors. Theranostics. 2020;10(6):2727\u201343.","journal-title":"Theranostics."},{"issue":"10","key":"8299_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07155-x","volume":"15","author":"J Wang","year":"2024","unstructured":"Wang J, Liu P, Zhang R, Xing B, Chen G, Han L, et al. VASH2 enhances KIF3C-mediated EGFR-endosomal recycling to promote aggression and chemoresistance of lung squamous cell carcinoma by increasing tubulin detyrosination. Cell Death Dis. 2024;15(10):772.","journal-title":"Cell Death Dis"},{"key":"8299_CR18","doi-asserted-by":"publisher","first-page":"104451","DOI":"10.1016\/j.ebiom.2023.104451","volume":"89","author":"J Yu","year":"2023","unstructured":"Yu J, Feng H, Sang Q, Li F, Chen M, Yu B, et al. VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer. EBioMedicine. 2023;89:104451.","journal-title":"EBioMedicine."},{"key":"8299_CR19","doi-asserted-by":"publisher","first-page":"867870","DOI":"10.3389\/fcell.2022.867870","volume":"10","author":"C Vineethakumari","year":"2022","unstructured":"Vineethakumari C, L\u00fcders J. Microtubule anchoring: attaching dynamic polymers to cellular structures. Front Cell Dev Biol. 2022;10:867870.","journal-title":"Front Cell Dev Biol"},{"key":"8299_CR20","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.tcb.2018.02.011","volume":"28","author":"M Martin","year":"2018","unstructured":"Martin M, Akhmanova A. Coming into focus: mechanisms of microtubule minus-end organization. Trends Cell Biol. 2018;28:574\u201388.","journal-title":"Trends Cell Biol"},{"key":"8299_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24067-y","volume":"12","author":"N Yagi","year":"2021","unstructured":"Yagi N, Kato T, Matsunaga S, Ehrhardt DW, Nakamura M, Hashimoto T. An anchoring complex recruits katanin for microtubule severing at the plant cortical nucleation sites. Nat Commun. 2021;12:3687.","journal-title":"Nat Commun"},{"key":"8299_CR22","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.1242\/jcs.03227","volume":"119","author":"F Bartolini","year":"2006","unstructured":"Bartolini F, Gundersen GG. Generation of noncentrosomal microtubule arrays. J Cell Sci. 2006;119:4155\u201363.","journal-title":"J Cell Sci"},{"key":"8299_CR23","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1073\/pnas.94.10.5078","volume":"94","author":"TJ Keating","year":"1997","unstructured":"Keating TJ, Peloquin JG, Rodionov VI, Momcilovic D, Borisy GG. Microtubule release from the centrosome. Proc Natl Acad Sci USA. 1997;94:5078\u201383.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8299_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0854.2003.00149.x","volume":"5","author":"A M\u00fcsch","year":"2004","unstructured":"M\u00fcsch A. Microtubule organization and function in epithelial cells. Traffic. 2004;5:1\u20139.","journal-title":"Traffic."},{"key":"8299_CR25","doi-asserted-by":"publisher","first-page":"121655","DOI":"10.1016\/j.lfs.2023.121655","volume":"322","author":"S Seephan","year":"2023","unstructured":"Seephan S, Sasaki SI, Wattanathamsan O, Singharajkomron N, He K, Ucche S, et al. CAMSAP3 negatively regulates lung cancer cell invasion and angiogenesis through nucleolin\/HIF-1\u03b1 mRNA complex stabilization. Life Sci. 2023;322:121655.","journal-title":"Life Sci"},{"key":"8299_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-016-0268-z","volume":"9","author":"S Wang","year":"2016","unstructured":"Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.","journal-title":"J Hematol Oncol"},{"key":"8299_CR27","doi-asserted-by":"publisher","first-page":"945102","DOI":"10.3389\/fonc.2022.945102","volume":"12","author":"Q Guo","year":"2022","unstructured":"Guo Q, Liu L, Chen Z, Fan Y, Zhou Y, Yuan Z, et al. Current treatments for non-small cell lung cancer. Front Oncol. 2022;12:945102.","journal-title":"Front Oncol"},{"key":"8299_CR28","doi-asserted-by":"publisher","first-page":"9356","DOI":"10.1158\/0008-5472.CAN-07-0509","volume":"67","author":"PP Gan","year":"2007","unstructured":"Gan PP, Pasquier E, Kavallaris M. Class III \u03b2-tubulin mediates sensitivity to chemotherapeutic drugs in non\u2013small cell lung cancer. Cancer Res. 2007;67:9356\u201363.","journal-title":"Cancer Res"},{"key":"8299_CR29","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","volume":"16","author":"JC Soria","year":"2015","unstructured":"Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16:990\u20138.","journal-title":"Lancet Oncol"},{"key":"8299_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41591-018-0264-7","volume":"25","author":"KN Shah","year":"2019","unstructured":"Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, et al. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat Med. 2019;25:111\u20138.","journal-title":"Nat Med"},{"key":"8299_CR31","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1080\/15384101.2017.1348080","volume":"16","author":"R Alfaro-Aco","year":"2017","unstructured":"Alfaro-Aco R, Petry S. How TPX2 helps microtubules branch out. Cell Cycle. 2017;16:1560\u20131.","journal-title":"Cell Cycle"},{"key":"8299_CR32","doi-asserted-by":"publisher","first-page":"167116","DOI":"10.1016\/j.bbadis.2024.167116","volume":"1870","author":"FD Naso","year":"2024","unstructured":"Naso FD, Polverino F, Cilluffo D, Latini L, Stagni V, Asteriti IA, et al. AurkA\/TPX2 co-overexpression in nontransformed cells promotes genome instability through induction of chromosome mis-segregation and attenuation of the p53 signalling pathway. Biochim Biophys Acta Mol Basis Dis. 2024;1870:167116.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"8299_CR33","doi-asserted-by":"publisher","first-page":"4416s","DOI":"10.1158\/1078-0432.CCR-06-0555","volume":"12","author":"PA J\u00e4nne","year":"2006","unstructured":"J\u00e4nne PA, Johnson BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res. 2006;12:4416s\u201320s.","journal-title":"Clin Cancer Res"},{"key":"8299_CR34","doi-asserted-by":"publisher","first-page":"20932","DOI":"10.1073\/pnas.0710370104","volume":"104","author":"J Bean","year":"2007","unstructured":"Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 2007;104:20932\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8299_CR35","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","volume":"11","author":"BT Li","year":"2016","unstructured":"Li BT, Ross DS, Aisner DL, Chaft JE, Hsu M, Kako SL, et al. HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. J Thorac Oncol. 2016;11:414\u20139.","journal-title":"J Thorac Oncol"},{"key":"8299_CR36","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/ng.2330","volume":"44","author":"Z Zhang","year":"2012","unstructured":"Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012;44:852\u201360.","journal-title":"Nat Genet"},{"key":"8299_CR37","doi-asserted-by":"publisher","first-page":"E2127","DOI":"10.1073\/pnas.1203530109","volume":"109","author":"K Ohashi","year":"2012","unstructured":"Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA. 2012;109:E2127\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8299_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05626-2","volume":"9","author":"RR Arasada","year":"2018","unstructured":"Arasada RR, Shilo K, Yamada T, Zhang J, Yano S, Ghanem R, et al. Notch3-dependent \u03b2-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. Nat Commun. 2018;9:3198.","journal-title":"Nat Commun"},{"key":"8299_CR39","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.celrep.2016.12.061","volume":"18","author":"M Momcilovic","year":"2017","unstructured":"Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, et al. Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR mutant lung cancer. Cell Rep. 2017;18:601\u201310.","journal-title":"Cell Rep"},{"key":"8299_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17385-0","volume":"11","author":"JJ Yu","year":"2020","unstructured":"Yu JJ, Zhou DD, Yang XX, Cui B, Tan FW, Wang J, et al. TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target. Nat Commun. 2020;11:3660.","journal-title":"Nat Commun"},{"key":"8299_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05370-y","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Chen C, Ling C, Luo S, Xiong Z, Liu X, et al. EGFR tyrosine kinase activity and Rab GTPases coordinate EGFR trafficking to regulate macrophage activation in sepsis. Cell Death Dis. 2022;13:934.","journal-title":"Cell Death Dis"},{"key":"8299_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-006-9244-6","volume":"100","author":"D Palmieri","year":"2006","unstructured":"Palmieri D, Bouadis A, Ronchetti R, Merino MJ, Steeg PS. Rab11a differentially modulates epidermal growth factor-induced proliferation and motility in immortal breast cells. Breast Cancer Res Treat. 2006;100:127\u201337.","journal-title":"Breast Cancer Res Treat"},{"key":"8299_CR43","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1200\/JCO.2010.34.0570","volume":"29","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 2011;29:3307\u201315.","journal-title":"J Clin Oncol"},{"key":"8299_CR44","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22:262\u20139.","journal-title":"Nat Med"},{"key":"8299_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1242\/jcs.216168","volume":"131","author":"V Pongrakhananon","year":"2018","unstructured":"Pongrakhananon V, Wattanathamsan O, Takeichi M, Chetprayoon P, Chanvorachote P. Loss of CAMSAP3 promotes EMT via the modification of microtubule\u2013Akt machinery. J Cell Sci. 2018;131:21.","journal-title":"J Cell Sci"},{"key":"8299_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02039-2","volume":"23","author":"X Mao","year":"2024","unstructured":"Mao X, Tang X, Ye J, Xu S, Wang Y, Liu X, et al. Multi-omics profiling reveal cells with novel oncogenic cluster, TRAP1(low)\/CAMSAP3(low), emerge more aggressive behavior and poor-prognosis in early-stage endometrial cancer. Mol Cancer. 2024;23:127.","journal-title":"Mol Cancer"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08299-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08299-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08299-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:02:32Z","timestamp":1769184152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08299-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8299"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08299-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6539573\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"27 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal protocols were approved by the Animal Care and Use Committee of the School of Life Science and Technology, Xi\u2019an Jiaotong University (Approval ID: AE-2025-2589), following the guidelines and regulations established by the university\u2019s Animal Care and Use Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"90"}}